
Enhertu Combo Receives FDA Designation in Metastatic HER2+ Breast Cancer
The United States Food and Drug Administration (FDA) has granted breakthrough therapy designation to first-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) plus Perjeta (pertuzumab) for patients with unresectable or metastatic HER2-positive …